{"id":"W4322604179","doi":"10.1016/s0140-6736(23)00350-1","title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; University of Alberta; Ottawa Allergy Research Corporation; University of Ottawa","funders":"Sanofi Genzyme; Genentech; Esperion Therapeutics; Glenmark Pharmaceuticals; BioCryst; Dermira; Regeneron Pharmaceuticals; Galderma; Eli Lilly and Company; Aimmune Therapeutics; CSL Behring; AstraZeneca; Celgene; Sanofi; Torii Pharmaceutical; Amgen","keywords":"Hereditary angioedema; Medicine; Placebo; Internal medicine; Angioedema; C1-inhibitor; Randomized controlled trial; Clinical endpoint; Clinical trial; Adverse effect; Pediatrics; Surgery; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008584335,0.0002694869,0.00121402,0.00008592862,0.0001739388,0.00003603735,0.0001539333,0.0001376185,0.00008785559],"category_scores_gemma":[0.0004755604,0.0001833414,0.0004167183,0.0003094385,0.0001180143,0.0001144103,0.00004585829,0.0001111008,0.00001713852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005121253,"about_ca_system_score_gemma":0.0001303562,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003921909,"about_ca_topic_score_gemma":0.00004036588,"domain_scores_codex":[0.9979863,0.0001299873,0.0007385815,0.0003468056,0.0003501199,0.0004481743],"domain_scores_gemma":[0.9981475,0.0008279221,0.000328064,0.0004449046,0.0001113307,0.0001402541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9785811,0.0004487982,0.0002732243,0.0001903147,0.0005230778,0.00001059987,0.0007735185,0.00002237848,0.0004779547,0.0001417646,0.00970765,0.008849586],"study_design_scores_gemma":[0.9877453,0.00103634,0.001719442,0.0002404725,0.0007117798,0.00001830818,0.0002448373,0.002270121,0.0007286418,0.0002019142,0.004895047,0.0001878023],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836028,0.002466901,0.0002941425,0.002196302,0.0006942851,0.009928178,0.0003044771,0.0001828832,0.0003300492],"genre_scores_gemma":[0.9944377,0.0002309001,0.0003111269,0.0001520888,0.003093157,0.0004182535,0.0002921108,0.00003510575,0.00102956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01083492,"threshold_uncertainty_score":0.7476444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06359225437290582,"score_gpt":0.3624595837101497,"score_spread":0.2988673293372439,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}